Cornerstone Capital Management Holdings LLC. Has $6.08 Million Stake in Bio-Rad Laboratories, Inc. (BIO)

Cornerstone Capital Management Holdings LLC. raised its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 727.2% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 26,866 shares of the medical research company’s stock after acquiring an additional 23,618 shares during the quarter. Cornerstone Capital Management Holdings LLC. owned approximately 0.09% of Bio-Rad Laboratories worth $6,079,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also modified their holdings of the company. Capital Analysts LLC purchased a new position in shares of Bio-Rad Laboratories during the 2nd quarter worth $170,000. BNP Paribas Arbitrage SA raised its position in shares of Bio-Rad Laboratories by 63.0% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 7,882 shares of the medical research company’s stock valued at $1,784,000 after purchasing an additional 3,047 shares during the period. Schwab Charles Investment Management Inc. raised its position in shares of Bio-Rad Laboratories by 1.8% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 115,218 shares of the medical research company’s stock valued at $26,075,000 after purchasing an additional 2,070 shares during the period. Credit Suisse AG raised its position in shares of Bio-Rad Laboratories by 25.4% during the 1st quarter. Credit Suisse AG now owns 20,604 shares of the medical research company’s stock valued at $4,108,000 after purchasing an additional 4,177 shares during the period. Finally, Legal & General Group Plc raised its position in shares of Bio-Rad Laboratories by 16.1% during the 2nd quarter. Legal & General Group Plc now owns 22,419 shares of the medical research company’s stock valued at $5,074,000 after purchasing an additional 3,107 shares during the period. Institutional investors and hedge funds own 62.84% of the company’s stock.

Shares of Bio-Rad Laboratories, Inc. (NYSE BIO) opened at 222.67 on Wednesday. Bio-Rad Laboratories, Inc. has a 12 month low of $154.89 and a 12 month high of $242.79. The stock’s 50 day moving average is $222.12 and its 200 day moving average is $220.81. The company has a market capitalization of $6.60 billion, a P/E ratio of 440.06 and a beta of 0.91.

Several brokerages have recently commented on BIO. Zacks Investment Research upgraded shares of Bio-Rad Laboratories from a “sell” rating to a “hold” rating in a research report on Wednesday, October 4th. Jefferies Group LLC restated a “buy” rating and set a $275.00 price objective on shares of Bio-Rad Laboratories in a research report on Friday, July 14th. BidaskClub downgraded shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday, June 14th. Deutsche Bank AG restated a “buy” rating and set a $255.00 price objective on shares of Bio-Rad Laboratories in a research report on Monday, September 18th. Finally, TheStreet downgraded shares of Bio-Rad Laboratories from a “b” rating to a “c+” rating in a research report on Thursday, August 3rd. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. Bio-Rad Laboratories has a consensus rating of “Buy” and a consensus price target of $240.00.

TRADEMARK VIOLATION WARNING: This piece was first posted by Community Financial News and is the property of of Community Financial News. If you are viewing this piece on another publication, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark legislation. The original version of this piece can be viewed at https://www.com-unik.info/2017/10/11/cornerstone-capital-management-holdings-llc-has-6-08-million-stake-in-bio-rad-laboratories-inc-bio.html.

In related news, EVP Michael Crowley sold 700 shares of the stock in a transaction on Friday, August 11th. The shares were sold at an average price of $215.91, for a total transaction of $151,137.00. Following the sale, the executive vice president now directly owns 2,060 shares of the company’s stock, valued at $444,774.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 28.29% of the company’s stock.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.

Institutional Ownership by Quarter for Bio-Rad Laboratories (NYSE:BIO)

What are top analysts saying about Bio-Rad Laboratories Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Bio-Rad Laboratories Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit